Health Center Monthly Service Delivery Report (Yekatit 2013 Megabit 2013 Tir 2013)

4/1/2021 Dataset Report
Health Center Monthly Service Delivery Report (Yekatit 2013;

Megabit 2013; Tir 2013)
Bulalafurfursa
S.No Activity
PHCU
RMH_FP_CAR Contraceptive acceptance rate
FP_CAR_Age Total new and repeat acceptors, disaggregated by age 71
FP_CAR_Age_New Contraceptive new acceptors by age 43
FP_CAR_Age_New. 1 10 - 14 years 4
FP_CAR_Age_Rep Contraceptive repeat acceptors by age 28
FP_CAR_Age_Rep. 1 10 - 14 years 2
FP_CAR_MTd Total new and repeat acceptors, disaggregated by method 32
FP_CAR_Mtd_New Contraceptive new acceptors, by method 11
FP_CAR_Mtd_New. 1 Oral contraceptives 3
FP_CAR_Mtd_New. 2 Injectables 4
FP_CAR_Mtd_New. 3 Implants 4
FP_CAR_Mtd_New. 4 IUD 0
FP_CAR_Mtd_New. 5 Vasectomy 0
FP_CAR_Mtd_New. 6 Tubal ligation 0
FP_CAR_Mtd_New. 7 Others 0
FP_CAR_Mtd_Rep Contraceptive repeat acceptors, by method 21
FP_CAR_Mtd_Rep. 1 Oral contraceptives 5
FP_CAR_Mtd_Rep. 2 Injectables 10
FP_CAR_Mtd_Rep. 3 Implants 6
FP_CAR_Mtd_Rep. 4 IUD 0
FP_CAR_Mtd_Rep. 5 Vasectomy 0
FP_CAR_Mtd_Rep. 6 Tubal ligation 0
FP_CAR_Mtd_Rep. 7 Others 0
RMH_FP_IPPF Immediate Postpartum Contraceptive Acceptance (IPPFP)
FP_IPPF_Age Total Immediate Postpartum Contraceptive acceptors disaggregated by age 0
FP_IPPF_Age. 1 10 - 14 years 0
169.254.112.165:8082/dhis-web-custom-report/index.html#/report 1/35

Bulalafurfursa
S.No Activity
PHCU
FP_IPPF_Mtd Total Immediate Postpartum Contraceptive acceptors disaggregated by method 0
FP_IPPF_Mtd. 1 Pills (POP) 0
FP_IPPF_Mtd. 2 Implants 0
FP_IPPF_Mtd. 3 IUD 0
FP_IPPF_Mtd. 4 Tubal ligation 0
FP_IPPF_Mtd. 5 Others 0
RMH_FP_LAFPPR Premature Removal of LAFP methods
FP_TtLAFPR. Total Long acting family planning (LAFP) removal in the reporting period 0
Total number of premature removal of Long acting family planning (LAFP) within 6
FP_LAFPPR_Pre 0
month insertion
FP_LAFPPR_Pre. 1 Implants 0
FP_LAFPPR_Pre. 2 IUD 0
FP_LAFPPR_Pre. 3 Others 0
RMH_ANC_1stV Antenatal Care coverage - First visit
ANC_1stV_GA.1 Number of pregnant women who received ANC first visit by gestational week 10
ANC_1stV_GA.1. 1 < 16 weeks gestation 3
ANC_1stV_GA.1. 2 >= 16 weeks gestation 7
Number of pregnant women that received Antenatal Care (ANC) at least once by
ANC_1stV_MA 10
maternal age
ANC_1stV_MA. 1 10 - 14 years 0
ANC_1stV_MA. 2 15 - 19 years 0
ANC_1stV_MA. 3 >= 20 years 10
Total number of pregnant women that received Antenatal Care (ANC): at least four
ANC_4thV_MA 10
visits by maternal age
ANC_4thV_MA. 1 10 - 14 years 0
ANC_4thV_MA. 2 15 - 19 years 0
ANC_4thV_MA. 3 >= 20 years 10
RMH_ANC_Syph Pregnant women attending antenatal care tested for syphilis
ANC_Syph Total number of pregnant women tested for syphilis 10
ANC_Syph. 1 Reactive 0
ANC_Syph. 2 Non-Reactive 10
ANC_Syph.RX. Total number of Reactive pregnant women treated for syphilis 0
RMH_ANC_Hepa Pregnant women attending antenatal care tested for hepatitis (B&C)
ANC_Hepa Total number of pregnant women tested for Hepatitis (B & C) 0
ANC_Hepa. 1 Reactive 0
ANC_Hepa. 2 Non-Reactive 0

Bulalafurfursa
S.No Activity
PHCU
ANC_Hepa_RX. Total number of pregnant women treated for Hepatitis (B&C) 0
RMH_L&D_SBA Births attended by skilled health personnel
L&D_SBA.1. Total number of births attended by skilled health personnel 35
RMH_L&D_SBR Still birth rate 0
L&D_SBR.SB. Number of still births 0
L&D_SBR.LB. Number of Live births 35
B&D_Ntfc Birth and death notifications
B&D_Ntfc.1. Number of birth notifications given 35
B&D_Ntfc.2. Number of death notifications given 0
RMH_PNC_E1stV Early Postnatal Care Coverage
PNC_E1stV.1 Number of Postnatal visits within 7 days of delivery 35
PNC_E1stV.1. 2 24Hrs (1day) 35
PNC_E1stV.1. 3 25 - 48 hrs (1 - 2 days) 0
PNC_E1stV.1. 4 49 - 72 hrs (2 - 3 days) 0
PNC_E1stV.1. 5 73 hrs - 7 days (4 - 7 days) 0
RMH_L&D_CS Caesarean section
L&D_CS. Number of women having given birth by caesarean section 0
Number of women receiving comprehensive abortion care services dis
RMH_CAC 0
aggregated by maternal age
RMH_CAC_SAC Number of safe abortions performed 0
RMH_CAC_SAC. 1 10 - 14 years 0
RMH_CAC_SAC. 5 >= 30 years 0
RMH_CAC_PAC Number of post abortion/emergency care 0
RMH_CAC_PAC. 1 10 - 14 years 0
RMH_CAC_PAC. 5 >= 30 years 0
Number of women receiving comprehensive abortion care disaggregated by
RMH_CAC 0
trimester
RMH_CAC. 1 First trimester(<12 Weeks) 0
RMH_CAC. 2 Second trimester(>=12 Weeks) 0
RMH_IMD_IMMR Institutional maternal deaths
IMD_IMMR. Number of maternal deaths in health facility 0

Bulalafurfursa
S.No Activity
PHCU
TngP_TPR Total number of teenage girls tested positive for pregnancy 0
TngP_TPR. 1 10 - 14 years 0
TngP_TPR. 2 15 - 19 years 0
RMH_TtP. Total number of women tested positive pregnancy 0
RMH_PMTCT PMTCT (Prevention of HIV Mother to Child Transmission)
PMTCT_TST_1. Number of pregnant women tested and know their HIV result during pregnancy 55
PMTCT_TST_2. Number of pregnant women tested and know their HIV result during labour & delivery 0
PMTCT_TST_3. Number of women tested and know their HIV result during the postpartum period 0
Number of women with known HIV positive status attending ANC, delivery and
PMTCT_KNpos. 0
postpartum for new pregnancy linked from Pre ART and ART
PMTCT_NWpos. Number of new HIV positive women during ANC, L&D and Postpartum 0
The facility provides PMTCT and/or ART service 0
Percentage of HIV-positive pregnant women who received ART to reduce
RMH_PMTCT_ARV the risk of Women-to child-transmission (MTCT) during pregnancy, L&D
and PNC
Number of HIV positive women who received ART to reduce the risk of mother to child
PMTCT_ARV_1.
transmission during ANC for the first time
Number of HIV positive Pregnant women who received ART to reduce the risk of mother
PMTCT_ARV_2.
to child transmission during L&D for the first time
Number of HIV positive lactating women who received ART to reduce the risk of mother
PMTCT_ARV_3.
to child transmission during PNC for the first time
PMTCT_ARV_4. Number of HIV-positive women who get pregnant while on ART and linked to ANC
Total number of infants within 12 months received virological test result 0
Number of HIV exposed infants who received a virological HIV test 0-2 Months of
PMTCT_IPCR.1
birth
PMTCT_IPCR.1. 1 Positive
PMTCT_IPCR.1. 2 Negative
Number of HIV exposed infants who received a virological HIV test 2-12 Months of
PMTCT_IPCR.1.2
birth
PMTCT_IPCR.1.2. 1 Positive
PMTCT_IPCR.1.2. 2 Negative
Percentage of Infants born to HIV-infected women started on co-
RMH_PMTCT_ICPT
trimoxazole prophylaxis within two months of birth
Number of infants born to HIV positive women started on co-trimoxazole prophylaxis
PMTCT_ICPT.1.
within two months of birth
Percentage of Infants born to HIV-infected women receiving antiretroviral
RMH_PMTCT_IARV
(ARV) prophylaxis for prevention of Women-to-child transmission (PMTCT)
PMTCT_IARV_1. Number of HIV exposed infants who received ARV prophylaxis For 6 weeks
PMTCT_IARV_2. Number of HIV exposed infants who received ARV prophylaxis For 12 weeks

Bulalafurfursa
S.No Activity
PHCU
RMH_L&D_pos. Number of HIV positive women who gave birth at health institution
Percentage of partners of pregnant, laboring and lactating women tested
RMH_PMTCT_PRN_TST
for HIV
Number of partners of pregnant, laboring and lactating women tested for HIV and know
PMTCT_PRN_TST.
their results
Number of partners of pregnant, laboring and lactating women whose test result is HIV
PMTCT_PRN_Pos.
positive
Number of HIV exposed infants receiving HIV confirmatory (antibody test) by 18
RMH_PMTCT_IABT
months
RMH_PMTCT_IABT. 1 Positive
RMH_PMTCT_IABT. 2 Negative
NCH_EPI Expanded Program of Immunization (EPI)
EPI_BCG. Number of children under one year of age who have received BCG vaccine
Number of children under one year of age who have received first dose of pentavalent
EPI_Penta1.
vaccine
Number of children under one year of age who have received third dose of pentavalent
EPI_Penta3.
vaccine
Number of children under one year of age who have received first dose of pneumococcal
EPI_PCV1.
vaccine
Number of children under one year of age who have received third dose of
EPI_PCV3.
pneumococcal vaccine
EPI_PV1. Number of children under one year of age who have received first dose of polio vaccine
EPI_PV3. Number of children under one year of age who have received third dose of Polio vaccine
Number of children under one year of age who have received one dose of inactivated
EPI_IPV.
polio vaccine
Number of children under one year of age who have received first dose of Rotavirus
EPI_RT1.
vaccine
Number of children under one year of age who have received 2nd dose of Rotavirus
EPI_RT2.
vaccine
Number of children under one year of age who have received first dose of measles
EPI_MCV1.
vaccine
EPI_FI. Number of children received all vaccine doses before 1st birthday
Number of children under two years of age who have received second dose of measles
EPI_MCV2.
vaccine
EPI_PAB. Number of Infants whose mothers had protective doses of TT against NNT (PAB)
EPI_HPV HPV Vaccination
Number of girls 14 year of age who have received first dose of human papilloma virus
EPI_HPV1.
vaccine
Number of girls 14 years of age who have received second dose of human
EPI_HPV2.
papillomavirus vaccine in 6 month interval from the first dose

Bulalafurfursa
S.No Activity
PHCU
RMH_MV_TT TT Vaccination
MV_TT1. Number of women who have received TT1 vaccination
MV_TT2. Number of women who have received TT2 vaccination
MV.TT3. Number of women who have received TT3 vaccination
MV.TT4. Number of women who have received TT4 vaccination
MV.TT5.. Number of women who have received TT5 vaccination
HCSM_EPI_VWR Vaccine Wastage Rate
VWR_BCG BCG Vaccine wastage rate
VWR_BCG_giv. BCG doses given (all ages)
VWR_BCG_opn. BCG doses opened
VWR_BCG_dam. BCG doses damaged
VWR_BCG_dis. BCG doses expired
VWR_Penta Penta Vaccine wastage rate
VWR_Penta_giv. Pentavalent (DPT-HepB-Hib) doses given (all ages)
VWR_Penta_opn. Pentavalent (DPT-HepB-Hib) doses opened
VWR_Penta_dam. Pentavalent (DPT-HepB-Hib) doses damaged
VWR_Penta_dis. Pentavalent (DPT-HepB-Hib) doses expired
VWR_PCV PCV Vaccine wastage rate
VWR_PCV_giv. Pneumococcal conjugated vaccine doses given (all ages)
VWR_PCV_opn. Pneumococcal conjugated vaccine doses opened
VWR_PCV_dam. Pneumococcal conjugated vaccine doses damaged
VWR_PCV_dis. Pneumococcal conjugated vaccine doses expired
Rota Vaccine wastage rate
VWR_RT_giv. Rota doses give (all ages)
VWR_RT_opn. Rota doses opened
VWR_RT_dam. Rota doses damaged
VWR_RT_dis. Rota doses expired
VWR_PV Polio Vaccine wastage rate
VWR_PV_giv. Polio doses given (all ages)
VWR_PV_opn. Polio doses opened
VWR_PV_dam. Polio doses damaged
VWR_PV_dis. Polio doses expired
VWR_MCV Measles Vaccine wastage rate
VWR_MCV_giv. Measles doses given (all ages)
VWR_MCV_opn. Measles doses opened
VWR_MCV_dam. Measles doses damaged
VWR_MCV_dis. Measles doses expired

Bulalafurfursa
S.No Activity
PHCU
TT Vaccine wastage rate
VWR_TT_opn. TT doses given
VWR_TT_giv. TT doses opened
VWR_TT_dam. TT doses damaged
VWR_TT_dis. TT doses expired
VWR_IPV IPV Vaccine wastage rate
VWR_IPV_giv. IPV doses given
VWR_IPV_opn. IPV doses opened
VWR_IPV_dam. IPV doses damaged
VWR_IPV_dis. IPV doses expired
VWR_HPV HPV Vaccine wastage rate
VWR_HPV_giv. HPV doses given
VWR_HPV_opn. HPV doses opened
VWR_HPV_dam. HPV doses damaged
VWR_HPV_dis. HPV doses expired
NCH_CHIM_EIND Early institutional neonatal death
NCH_CHIM_EIND Number of neonatal deaths in the first 7 days of life(Institutional)
NCH_CHIM_EIND. 1 First 24 hrs of life
NCH_CHIM_EIND. 2 1-7 days of life
NCH_CHIM_PnRX Under-five children with pneumonia received antibiotic treatment
CHIM_PnRX. Number of under 5 children treated for pneumonia
NCH_CHIM_VSD Number of sick young infants 0-2 months treated for sepsis
CHIM_VSD_sep. Number of sick young infants 0-2 months treated for sepsis
CHIM_VSD_lbi. Number of sick young infants 0-2 months treated for local bacterial infection (LBI)
NCH_CHIM_DhRX Proportion of children who are treated for Diarrhea
CHIM_DhRX_orszinc. Number of children treated for diarrhea with ORS and zinc
CHIM_DhRX_orsonly. Number of children treated for diarrhea with ORS only
Proportion of low birth weight and/or premature newborns for whom KMC
NCH_CHIM_KMC
was initiated after delivery
Total number of newborns weighing <2000gm and/or premature newborns for which KMC
CHIM_KMC.1.
initiated
CHIM_E4KMC. Total number of newborns weighing <2000gm and/or premature
Asphyxiated neonates who were resuscitated (with bag & mask) and
NCH_CHIM_AsfxRS
survived
CHIM_AsfxRS. Total number of neonates resuscitated and survived
CHIM_AsfxR. Total number of neonates resuscitated
NCH_NTR Maternal and Child Nutrition

Bulalafurfursa
S.No Activity
PHCU
NCH_NTR_LBW Percentage of low birth weight (LBW) newborns
NTR_LBW_1. Number of live-born babies with birth weight less than 2500 gm
NTR_LBW_2. Total number of live births weighed
NCH_NTR_GMP Promotion of GMP participation among children under 2 yr
NTR_GMP Number of children less than 2 years weighted during GMP session
NTR_GMP. 1 0 - 5 months
NTR_GMP. 2 6 - 23 months
Number of weights recorded with moderate malnutrition by age (Z score b/n -2 &
NTR_GMP_MM
-3)
NTR_GMP_MM. 1 0 - 5 months
NTR_GMP_MM. 2 6 - 23 months
GMP_SM Number of weights recorded with severe malnutrition by age ( Z score below -3)
GMP_SM. 1 0 - 5 months
GMP_SM. 2 6 - 23 months
NTR_S4AM Children aged <5 yr screened for acute malnutrition
NTR_S4AM Total number of children <5yrs screened for acute malnutrition
NTR_S4AM. 1 0 - 5 months
NTR_S4AM. 2 6 - 59 months
S4AM_MAM Number of children <5 year screened and have moderate acute malnutrition
S4AM_MAM. 1 0 - 5 months
S4AM_MAM. 2 6 - 59 months
S4AM_SAM Number of children <5 year screened and have severe acute malnutrition
S4AM_SAM. 1 0 - 5 months
S4AM_SAM. 2 6 - 59 months
Treatment outcome for management of severe acute malnutrition in
NCH_NTR_SAM_RXO
children under 5 yr (OTP and SC)
NTR_SAM_RXO_1 Treatment outcome for management of SAM in children under 5 years
NTR_SAM_RXO_1. 1 Recovered
NTR_SAM_RXO_1. 2 Died
NTR_SAM_RXO_1. 3 Transferred out
NTR_SAM_RXO_1. 4 Defaulted
NTR_SAM_RXO_1. 5 Non-respondent
NTR_SAM_RXO_1. 6 Medical transfer
NTR_SAM_RXO_1. 7 Unknown status
Number of children who exit from severe acute malnutrition treatment during the reporting
NTR_SAM_Ext.
period
NTR_SAM_Adt. Number of children with SAM admitted to TFP(OTP &SC) during the reporting period

Bulalafurfursa
S.No Activity
PHCU
Total number of children aged 6-59 months who received Vitamin A
NTR_VAS_1
supplementation - by age
NTR_VAS_1. 1 6 - 11 months
NTR_VAS_1. 2 12 - 59 months
Total number of children aged 6-59 months who received Vitamin A
NTR_VAS_2
supplementation - by dose
NTR_VAS_2. 1 First dose
NTR_VAS_2. 2 Second dose
NTR_DWR Total number of children aged 24 - 59 months dewormed
NTR_DWR. 1 First dose
NTR_DWR. 2 Second dose
PLW_S4AM Total number of PLW screened for acute malnutrition
PLW_S4AM. 1 MUAC < 23 cm
PLW_S4AM. 2 MUAC >= 23 cm
ANC_IFA Total number of Pregnant women received IFA at least 90 plus
ANC_IFA. 1 10 - 14 years
ANC_IFA. 2 15 - 19 years
ANC_IFA. 3 >= 20 years
RMH_ANC_DWR. Number of pregnant women de-wormed
CDC_HIV HIV/AIDS
Number of individuals who have been tested for HIV and received their
HIV_HCT.1
results
HIV_VCT Clients receiving HIV test results at VCT
HIV_VCT. 1 < 1 year, Male
HIV_VCT. 2 < 1 year, Female
HIV_VCT. 3 1 - 4 years, Male
HIV_VCT. 4 1 - 4 years, Female
HIV_VCT. 15 >= 50 years, Male

Bulalafurfursa
S.No Activity
PHCU
HIV_VCT. 16 >= 50 years, Female
HIV_VCT_Pos.1 Clients testing positive for HIV at VCT
HIV_VCT_Pos.1. 1 < 1 year, Male
HIV_VCT_Pos.1. 2 < 1 year, Female
HIV_VCT_Pos.1. 3 1 - 4 years, Male
HIV_VCT_Pos.1. 4 1 - 4 years, Female
HIV_VCT_Pos.1. 15 >= 50 years, Male
HIV_VCT_Pos.1. 16 >= 50 years, Female
HIV_PITC Clients receiving HIV test results at PITC 55
HIV_PITC. 1 < 1 year, Male
HIV_PITC. 2 < 1 year, Female
HIV_PITC. 3 1 - 4 years, Male
HIV_PITC. 4 1 - 4 years, Female
HIV_PITC. 12 20 - 24 years, Female 55
HIV_PITC. 15 >= 50 years, Male
HIV_PITC. 16 >= 50 years, Female
HIV_PITC_Pos Clients testing positive for HIV at PITC
HIV_PITC_Pos. 1 < 1 year, Male

Bulalafurfursa
S.No Activity
PHCU
HIV_PITC_Pos. 2 < 1 year, Female
HIV_PITC_Pos. 3 1 - 4 years, Male
HIV_PITC_Pos. 4 1 - 4 years, Female
HIV_PITC_Pos. 15 >= 50 years, Male
HIV_PITC_Pos. 16 >= 50 years, Female
HIV_HCT_PG HCT by population group
HIV_HCT_PG.1. Female commercial Sex workers - received result
HIV_HCT_PG.1.1. Female commercial Sex workers - tested positive
HIV_HCT_PG.2. Long distance drivers - received result
HIV_HCT_PG.2.1. Long distance drivers - tested positive
HIV_HCT_PG.3. Mobile/Daily Laborers - received result
HIV_HCT_PG.3.1. Mobile/Daily Laborers - tested positive
HIV_HCT_PG.4. OVC - received result
HIV_HCT_PG.4.1. OVC - tested positive
HIV_HCT_PG.5. Children of PLHIV - received result
HIV_HCT_PG.5.1. Children of PLHIV - tested positive
HIV_HCT_PG.6. Prisoners - received result
HIV_HCT_PG.6.1. Prisoners - tested positive
HIV_HCT_PG.7. Partners of PLHIV - received result
HIV_HCT_PG.7.1. Partners of PLHIV - tested positive
HIV_HCT_PG.8. Other MARPs - received result
HIV_HCT_PG.8.1. Other MARPs - tested positive
HIV_HCT_PG.9. HCT in general population - received result
HIV_HCT_PG.9.1. HCT in general population - tested positive
CDC_STI_PITC STI Cases Tested for HIV in the Reporting Period
STI_PITC Number of STI cases tested for HIV
STI_PITC. 1 Positive, Male

Bulalafurfursa
S.No Activity
PHCU
STI_PITC. 2 Positive, Female
STI_PITC. 3 Negative, Male
STI_PITC. 4 Negative, Female
CDC_STI Total number of STI cases by sex
CDC_STI. 1 Male
CDC_STI. 2 Female
CDC_STI_Sy Total number of STI cases by syndrome
CDC_STI_Sy. 1 Urethral discharge
CDC_STI_Sy. 2 Persistent urethral discharge
CDC_STI_Sy. 3 Scrotal swelling
CDC_STI_Sy. 4 Vaginal discharge
CDC_STI_Sy. 5 PID (pelvic inflammatory disease)
CDC_STI_Sy. 6 Non vesicular genital ulcer disease (NVGUD)
CDC_STI_Sy. 7 Vesicular genital ulcer disease (VGUD)
CDC_STI_Sy. 8 Inguinal bubo
CDC_STI_Sy. 9 Neonatal conjunctivitis
CDC_STI_Sy. 10 Neonatal herpes
Number of adults and children who are currently on ART 0
Number of adults who are currently on ART by regimen type 0
HIV_RXC.1.1.1 Adult aged 15-19 yrs currently on ART 0
HIV_RXC.1.1.1.1 Adult 15-19 years currently on ART on first line regimen
HIV_RXC.1.1.1.1. 1 1c = AZT-3TC-NVP, Male
HIV_RXC.1.1.1.1. 2 1c = AZT-3TC-NVP, Female
HIV_RXC.1.1.1.1. 3 1d = AZT-3TC-EFV, Male
HIV_RXC.1.1.1.1. 4 1d = AZT-3TC-EFV, Female
HIV_RXC.1.1.1.1. 5 1e = TDF-3TC-EFV, Male
HIV_RXC.1.1.1.1. 6 1e = TDF-3TC-EFV, Female
HIV_RXC.1.1.1.1. 7 1f= TDF + 3TC+ NVP, Male
HIV_RXC.1.1.1.1. 8 1f= TDF + 3TC+ NVP, Female
HIV_RXC.1.1.1.1. 9 1g= ABC + 3TC + EFV, Male
HIV_RXC.1.1.1.1. 10 1g= ABC + 3TC + EFV, Female
HIV_RXC.1.1.1.1. 11 1h= ABC + 3TC NVP, Male
HIV_RXC.1.1.1.1. 12 1h= ABC + 3TC NVP, Female
HIV_RXC.1.1.1.1. 13 Others, Male
HIV_RXC.1.1.1.1. 14 Others, Female
HIV_RXC.1.1.1.1. 15 1j=TDF + 3TC + DTG, Male
HIV_RXC.1.1.1.1. 16 1j=TDF + 3TC + DTG, Female

Bulalafurfursa
S.No Activity
PHCU
HIV_RXC.1.1.1.1. 17 1k= AZT +3TC +DTG, Male
HIV_RXC.1.1.1.1. 18 1k= AZT +3TC +DTG, Female
HIV_RXC.1.1.1.1.2 Adult 15-19 years currently on ART on second line regimen
HIV_RXC.1.1.1.1.2. 1 2e= AZT+3TC+LPV/r, Male
HIV_RXC.1.1.1.1.2. 2 2e= AZT+3TC+LPV/r, Female
HIV_RXC.1.1.1.1.2. 3 2f=AZT+3TC+ATV/r, Male
HIV_RXC.1.1.1.1.2. 4 2f=AZT+3TC+ATV/r, Female
HIV_RXC.1.1.1.1.2. 5 2g= TDF-3TC-LPV/r, Male
HIV_RXC.1.1.1.1.2. 6 2g= TDF-3TC-LPV/r, Female
HIV_RXC.1.1.1.1.2. 7 2h =TDF-3TC-ATV/r, Male
HIV_RXC.1.1.1.1.2. 8 2h =TDF-3TC-ATV/r, Female
HIV_RXC.1.1.1.1.2. 9 2i = ABC + 3TC + LPV/r, Male
HIV_RXC.1.1.1.1.2. 10 2i = ABC + 3TC + LPV/r, Female
HIV_RXC.1.1.1.1.2. 11 Others, Male
HIV_RXC.1.1.1.1.2. 12 Others, Female
HIV_RXC.1.1.1.1.3 Adult 15-19 years currently on ART on third line regimen
HIV_RXC.1.1.1.1.3. 1 3a=DRV/r+DTG+AZT/3TC, Male
HIV_RXC.1.1.1.1.3. 2 3a=DRV/r+DTG+AZT/3TC, Female
HIV_RXC.1.1.1.1.3. 3 3b=DRV/r+DTG+TDF/3TC, Male
HIV_RXC.1.1.1.1.3. 4 3b=DRV/r+DTG+TDF/3TC, Female
HIV_RXC.1.1.1.1.3. 5 Others, Male
HIV_RXC.1.1.1.1.3. 6 Others, Female
HIV_RXC.1.1.1.1.3. 7 3d= DRV/r + ABC + EFV + 3TC, Male
HIV_RXC.1.1.1.1.3. 8 3d= DRV/r + ABC + EFV + 3TC, Female

Bulalafurfursa
S.No Activity
PHCU
HIV_RXC.1.1.2.2 Adult 20-24 years currently on ART on second line regimen
HIV_RXC.1.1.2.2. 1 2e= AZT+3TC+LPV/r, Male
HIV_RXC.1.1.2.2. 2 2e= AZT+3TC+LPV/r, Female
HIV_RXC.1.1.2.2. 3 2f=AZT+3TC+ATV/r, Male
HIV_RXC.1.1.2.2. 4 2f=AZT+3TC+ATV/r, Female
HIV_RXC.1.1.2.2. 5 2g= TDF-3TC-LPV/r, Male
HIV_RXC.1.1.2.2. 6 2g= TDF-3TC-LPV/r, Female
HIV_RXC.1.1.2.2. 7 2h =TDF-3TC-ATV/r, Male
HIV_RXC.1.1.2.2. 8 2h =TDF-3TC-ATV/r, Female
HIV_RXC.1.1.2.2. 9 2i = ABC + 3TC + LPV/r, Male
HIV_RXC.1.1.2.2. 10 2i = ABC + 3TC + LPV/r, Female
HIV_RXC.1.1.2.3 Adult 20-24 years currently on ART on third line regimen
HIV_RXC.1.1.2.3. 1 3a=DRV/r+DTG+AZT/3TC, Male
HIV_RXC.1.1.2.3. 2 3a=DRV/r+DTG+AZT/3TC, Female
HIV_RXC.1.1.2.3. 3 3b=DRV/r+DTG+TDF/3TC, Male
HIV_RXC.1.1.2.3. 4 3b=DRV/r+DTG+TDF/3TC, Female
HIV_RXC.1.1.2.3. 7 3d= DRV/r + ABC + EFV + 3TC, Male
HIV_RXC.1.1.2.3. 8 3d= DRV/r + ABC + EFV + 3TC, Female

Bulalafurfursa
S.No Activity
PHCU
HIV_RXC.1.1.3.2 Adult 25-49 years currently on ART on second line regimen
HIV_RXC.1.1.3.3 Adult 25-49 years currently on ART on third line regimen
HIV_RXC.1.1.4 Adult aged 50+ yrs currently on ART 0
HIV_RXC.1.1.4.1 Adult >=50 years currently on ART on first line regimen

Bulalafurfursa
S.No Activity
PHCU
HIV_RXC.1.1.4.2 Adult >=50 years currently on ART on second line regimen
HIV_RXC.1.1.4.3 Adult >=50 years currently on ART on third line regimen

Bulalafurfursa
S.No Activity
PHCU
Number of children who are currently on ART by regimen type 0
HIV_RXC.1.2.1 Children aged <1 yr currently on ART 0
HIV_RXC.1.2.1.1 Infants <1 years currently on ART on First Line Regimen
HIV_RXC.1.2.1.1. 3 4f=AZT + 3TC + LPV/r, Male
HIV_RXC.1.2.1.1. 4 4f=AZT + 3TC + LPV/r, Female
HIV_RXC.1.2.1.1. 5 4g=ABC + 3TC + LPV/r, Male
HIV_RXC.1.2.1.1. 6 4g=ABC + 3TC + LPV/r, Female
HIV_RXC.1.2.1.2 Infants <1 years currently on ART on second line regimen
HIV_RXC.1.2.1.2. 1 5e=ABC + 3TC + LPV/r, Male
HIV_RXC.1.2.1.2. 2 5e=ABC + 3TC + LPV/r, Female
HIV_RXC.1.2.1.2. 5 5j=ABC+ 3TC+ LPV/r, Male
HIV_RXC.1.2.1.2. 6 5j=ABC+ 3TC+ LPV/r, Female
HIV_RXC.1.2.1.2. 9 5k= RAL + AZT + 3TC, Male
HIV_RXC.1.2.1.2. 10 5k= RAL + AZT + 3TC, Female
HIV_RXC.1.2.1.2. 11 5l= RAL + ABC + 3TC, Male
HIV_RXC.1.2.1.2. 12 5l= RAL + ABC + 3TC, Female
HIV_RXC.1.2.2 Children aged 1-4 yrs currently on ART 0
HIV_RXC.1.2.2.1 Children 1 - 4 years currently on ART on first line regimen

Bulalafurfursa
S.No Activity
PHCU
HIV_RXC.1.2.2.1. 11 4j= ABC +3TC + DTG, Male
HIV_RXC.1.2.2.1. 12 4j= ABC +3TC + DTG, Female
HIV_RXC.1.2.2.1. 13 4k= AZT + 3TC + DTG, Male
HIV_RXC.1.2.2.1. 14 4k= AZT + 3TC + DTG, Female
HIV_RXC.1.2.2.1. 15 4l= ABC + 3TC + EFV, Male
HIV_RXC.1.2.2.1. 16 4l= ABC + 3TC + EFV, Female
HIV_RXC.1.2.2.2 Children 1 - 4 years currently on ART on second line regimen
HIV_RXC.1.2.2.2. 5 5h=ABC + 3TC + EFV, Male
HIV_RXC.1.2.2.2. 6 5h=ABC + 3TC + EFV, Female
HIV_RXC.1.2.2.2. 7 5j=ABC+ 3TC+ LPV/r, Male
HIV_RXC.1.2.2.2. 8 5j=ABC+ 3TC+ LPV/r, Female
HIV_RXC.1.2.2.2. 15 5m = ABC + 3TC + DTG, Male
HIV_RXC.1.2.2.2. 16 5m = ABC + 3TC + DTG, Female
HIV_RXC.1.2.2.2. 17 5n= AZT + 3TC + DTG, Male
HIV_RXC.1.2.2.2. 18 5n= AZT + 3TC + DTG, Female
HIV_RXC.1.2.2.3 Children 1 - 4 years currently on ART on third line regimen
HIV_RXC.1.2.2.3. 1 6a=DRV/r+RAL+AZT+3TC, Male
HIV_RXC.1.2.2.3. 2 6a=DRV/r+RAL+AZT+3TC, Female
HIV_RXC.1.2.2.3. 3 6b=DRV/r+RAL+TDF+3TC, Male
HIV_RXC.1.2.2.3. 4 6b=DRV/r+RAL+TDF+3TC, Female
HIV_RXC.1.2.2.3. 7 6c=DRV/r+DTG+AZT+3TC, Male
HIV_RXC.1.2.2.3. 8 6c=DRV/r+DTG+AZT+3TC, Female
HIV_RXC.1.2.2.3. 9 6f= DRV/r + DTG + ABC + 3TC, Male
HIV_RXC.1.2.2.3. 10 6f= DRV/r + DTG + ABC + 3TC, Female

Bulalafurfursa
S.No Activity
PHCU
HIV_RXC.1.2.3.1. 5 4e= TDF-3TC-EFV, Male
HIV_RXC.1.2.3.1. 6 4e= TDF-3TC-EFV, Female
HIV_RXC.1.2.3.2. 5 5g= TDF + 3TC + EFV, Male
HIV_RXC.1.2.3.2. 6 5g= TDF + 3TC + EFV, Female
HIV_RXC.1.2.3.2. 9 5i=TDF + 3TC+ LPV/r, Male
HIV_RXC.1.2.3.2. 10 5i=TDF + 3TC+ LPV/r, Female

Bulalafurfursa
S.No Activity
PHCU
HIV_RXC.1.2.4.1. 5 4e= TDF-3TC-EFV, Male
HIV_RXC.1.2.4.1. 6 4e= TDF-3TC-EFV, Female
HIV_RXC.1.2.4.1. 13 4i= TDF + 3TC + DTG, Male
HIV_RXC.1.2.4.1. 14 4i= TDF + 3TC + DTG, Female

Bulalafurfursa
S.No Activity
PHCU
HIV_RXC.1.2.4.2. 5 5g= TDF + 3TC + EFV, Male
HIV_RXC.1.2.4.2. 6 5g= TDF + 3TC + EFV, Female
HIV_RXC.1.2.4.2. 9 5i=TDF + 3TC+ LPV/r, Male
HIV_RXC.1.2.4.2. 10 5i=TDF + 3TC+ LPV/r, Female
HIV_RXC.1.2.4.3. 7 6d=DRV/r+DTG+TDF+3TC, Male
HIV_RXC.1.2.4.3. 8 6d=DRV/r+DTG+TDF+3TC, Female
HIV_RXC_LTF. Number of PLHIV who are documented as lost/lost to follow up
CDC_HIV_RXN Number of adults and children with HIV infection newly started on ART
CDC_HIV_RXN. 1 < 1 year, Male

Bulalafurfursa
S.No Activity
PHCU
CDC_HIV_RXN. 3 < 1 year, Female - non-pregnant
CDC_HIV_RXN. 4 1 - 4 years, Male
CDC_HIV_RXN. 6 1 - 4 years, Female - non-pregnant
CDC_HIV_RXN. 14 15 - 19 years, Female - pregnant
CDC_HIV_RXN. 22 >= 50 years, Male
CDC_HIV_RXN. 24 >= 50 years, Female - non-pregnant
Number of adults and children who are still on treatment at 12 months after
HIV_RtR_1
initiating ART
HIV_RtR_1. 1 < 1 year, Male
HIV_RtR_1. 3 < 1 year, Female - non-pregnant
HIV_RtR_1. 4 1 - 4 years, Male
HIV_RtR_1. 6 1 - 4 years, Female - non-pregnant
HIV_RtR_1. 14 15 - 19 years, Female - pregnant
HIV_RtR_1. 22 >= 50 years, Male

Bulalafurfursa
S.No Activity
PHCU
HIV_RtR_1. 24 >= 50 years, Female - non-pregnant
Number of persons on ART in the original cohort including those transferred in,
HIV_NCC
minus those transferred out (net current cohort)
HIV_NCC. 1 < 1 year, Male
HIV_NCC. 3 < 1 year, Female - non-pregnant
HIV_NCC. 4 1 - 4 years, Male
HIV_NCC. 6 1 - 4 years, Female - non-pregnant
HIV_NCC. 14 15 - 19 years, Female - pregnant
HIV_NCC. 22 >= 50 years, Male
HIV_NCC. 24 >= 50 years, Female - non-pregnant
Percentage of ART clients with undetectable viral load at 6 month after
initiation of ART
Number of adult and pediatric patients with an undetectable viral load <1,000
HIV_UVLC_6M
copies/ml at 6 months
HIV_UVLC_6M. 1 < 1 year, Male
HIV_UVLC_6M. 3 < 1 year, Female - non-pregnant
HIV_UVLC_6M. 4 1 - 4 years, Male
HIV_UVLC_6M. 6 1 - 4 years, Female - non-pregnant
HIV_UVLC_6M. 14 15 - 19 years, Female - pregnant

Bulalafurfursa
S.No Activity
PHCU
HIV_UVLC_6M. 22 >= 50 years, Male
HIV_UVLC_6M. 24 >= 50 years, Female - non-pregnant
Number of adults and children who initiated ART in the 6 months prior to the
HIV_VLC_6M
beginning of the reporting period with a viral load count at 6 month visit
HIV_VLC_6M. 1 < 1 year, Male
HIV_VLC_6M. 3 < 1 year, Female - non-pregnant
HIV_VLC_6M. 4 1 - 4 years, Male
HIV_VLC_6M. 6 1 - 4 years, Female - non-pregnant
HIV_VLC_6M. 14 15 - 19 years, Female - pregnant
HIV_VLC_6M. 22 >= 50 years, Male
HIV_VLC_6M. 24 >= 50 years, Female - non-pregnant
Number of adult and pediatric patients with an undetectable viral load <1,000
HIV_SVLC
copies/ml in the reporting period
HIV_SVLC. 1 < 1 year, Male
HIV_SVLC. 3 < 1 year, Female - non-pregnant
HIV_SVLC. 4 1 - 4 years, Male
HIV_SVLC. 6 1 - 4 years, Female - non-pregnant

Bulalafurfursa
S.No Activity
PHCU
HIV_SVLC. 14 15 - 19 years, Female - pregnant
HIV_SVLC. 22 >= 50 years, Male
HIV_SVLC. 24 >= 50 years, Female - non-pregnant
Number of adult and pediatric ART patients at 12 month (yearly) viral load test in
HIV_VLC
the reporting period
HIV_VLC. 1 < 1 year, Male
HIV_VLC. 3 < 1 year, Female - non-pregnant
HIV_VLC. 4 1 - 4 years, Male
HIV_VLC. 6 1 - 4 years, Female - non-pregnant
HIV_VLC. 14 15 - 19 years, Female - pregnant
HIV_VLC. 22 >= 50 years, Male
HIV_VLC. 24 >= 50 years, Female - non-pregnant
HIV_NTR_S4M Number of PLHIV who were assessed/screened for malnutrition
HIV_NTR_S4M. 1 < 1 year, Male
HIV_NTR_S4M. 3 < 1 year, Female - non-pregnant
HIV_NTR_S4M. 4 1 - 4 years, Male
HIV_NTR_S4M. 6 1 - 4 years, Female - non-pregnant

Bulalafurfursa
S.No Activity
PHCU
HIV_NTR_S4M. 14 15 - 19 years, Female - pregnant
HIV_NTR_S4M. 22 >= 50 years, Male
HIV_NTR_S4M. 24 >= 50 years, Female - non-pregnant
Number of PLHIV that were nutritionally assessed and found to be clinically
HIV_NTR_S4MU.1
undernourished - by age sex and pregnancy
HIV_NTR_S4MU.1. 1 < 1 year, Male
HIV_NTR_S4MU.1. 3 < 1 year, Female - non-pregnant
HIV_NTR_S4MU.1. 4 1 - 4 years, Male
HIV_NTR_S4MU.1. 6 1 - 4 years, Female - non-pregnant
HIV_NTR_S4MU.1. 14 15 - 19 years, Female - pregnant
HIV_NTR_S4MU.1. 22 >= 50 years, Male
HIV_NTR_S4MU.1. 24 >= 50 years, Female - non-pregnant
Number of PLHIV that were nutritionally assessed and found to be clinically
HIV_NTR_S4MU.2
undernourished - by nutritional status
HIV_NTR_S4MU.2. 1 MAM

Bulalafurfursa
S.No Activity
PHCU
HIV_NTR_S4MU.2. 2 SAM
Number of clinically undernourished PLHIV who received therapeutic or
HIV_NTR_S4MU_TF.1
supplementary food by age sex and pregnancy status
HIV_NTR_S4MU_TF.1. 1 < 1 year, Male
HIV_NTR_S4MU_TF.1. 3 < 1 year, Female - non-pregnant
HIV_NTR_S4MU_TF.1. 4 1 - 4 years, Male
HIV_NTR_S4MU_TF.1. 6 1 - 4 years, Female - non-pregnant
HIV_NTR_S4MU_TF.1. 14 15 - 19 years, Female - pregnant
HIV_NTR_S4MU_TF.1. 22 >= 50 years, Male
HIV_NTR_S4MU_TF.1. 24 >= 50 years, Female - non-pregnant
Number of clinically undernourished PLHIV who received therapeutic or
HIV_NTR_S4MU_TF.2
supplementary food - by nutritional status
HIV_NTR_S4MU_TF.2. 1 MAM
HIV_NTR_S4MU_TF.2. 2 SAM
Number of persons provided with post-exposure prophylaxis (PEP) for risk of HIV
HIV_PEP.1
infection
HIV_PEP.1. 1 Non occupational risk
HIV_PEP.1. 2 Occupational risk
HIV_PE4HIV Number of persons exposed for HIV infection eligible for PEP
HIV_PE4HIV. 1 Non occupational risk
HIV_PE4HIV. 2 Occupational risk
Number of PLHIV women aged 15-49 reporting the use of any method of modern
HIV_FP_Mtd
family planning
HIV_FP_Mtd. 1 Long acting
HIV_FP_Mtd. 2 Short acting

Bulalafurfursa
S.No Activity
PHCU
Number of PLHIV women aged 15-49 reporting the use of any method of modern
HIV_FP_Age
family planning by age
HIV_FP_Age. 1 10 - 14 years
Number of clients enrolled in HIV care who were screened for TB during the
HIV_TBSC.1
reporting period
HIV_TBSC.1. 1 < 1 year, Male
HIV_TBSC.1. 3 < 1 year, Female - non-pregnant
HIV_TBSC.1. 4 1 - 4 years, Male
HIV_TBSC.1. 6 1 - 4 years, Female - non-pregnant
HIV_TBSC.1. 14 15 - 19 years, Female - pregnant
HIV_TBSC.1. 22 >= 50 years, Male
HIV_TBSC.1. 24 >= 50 years, Female - non-pregnant
Total number of HIV positive clients identified with active TB during reporting
HIV_TBPos.1
period
HIV_TBPos.1. 1 < 15 years, Male
HIV_TBPos.1. 2 < 15 years, Female
HIV_TBPos.1. 3 >= 15 years, Male
HIV_TBPos.1. 4 >= 15 years, Female
HIV_TBPos.2 Total number of newly started ART clients with active TB in the reporting period
HIV_TBPos.2. 1 < 15 years, Male
HIV_TBPos.2. 2 < 15 years, Female
HIV_TBPos.2. 3 >= 15 years, Male
HIV_TBPos.2. 4 >= 15 years, Female

Bulalafurfursa
S.No Activity
PHCU
HIV_IPTE1 Total number of newly enrolled ART clients initiated on LTBI Treatment - IPT
HIV_IPTE1. 1 < 15 years, Male
HIV_IPTE1. 2 < 15 years, Female
HIV_IPTE1. 3 >= 15 years, Male
HIV_IPTE1. 4 >= 15 years, Female
HIV_IPTE2 Total number of newly enrolled ART clients initiated on LTBI Treatment - 3HP
HIV_IPTE2. 1 < 15 years, Male
HIV_IPTE2. 2 < 15 years, Female
HIV_IPTE2. 3 >= 15 years, Male
HIV_IPTE2. 4 >= 15 years, Female
Total number of PLHIV completed LTBI treatment (receiving IPT/3HP) during the
HIV_IPT_CRX.1_Type
reporting period
HIV_IPT_CRX.1_Type. 1 IPT
HIV_IPT_CRX.1_Type. 2 3HP
HIV_IPT_ASM.1.1 Total number of adult PLHIV newly enrolled for ASM in the reporting period
HIV_IPT_ASM.1.1. 1 Male
HIV_IPT_ASM.1.1. 2 Female
HIV_IPT_ASM.1.2 Total number of adult PLHIV currently on ASM in the reporting period
HIV_IPT_ASM.1.2. 1 Male
HIV_IPT_ASM.1.2. 2 Female
Total number of clients identified for pre-Exposure prophylaxis in the reporting
HIV_IPT_PreE.1
period
HIV_IPT_PreE.1. 1 Sero discordant
HIV_IPT_PreE.1. 2 Female sex worker
Total number of clients newly enrolled on Pre-Exposure prohylaxis (PrEP) in the
HIV_IPT_PreE.2
reporting period
Total number of clients completed Pre-exposure prohylaxis (PrEP) in the reporting
HIV_IPT_PreE.3
period
CDC_Mal Malaria
Mal_Pos Malaria positivity rate
Mal_Pos.1 Number of slides or RDT positive for malaria
Mal_Pos.1. 1 < 5 years, Male
Mal_Pos.1. 2 < 5 years, Female
Mal_Pos.1. 3 5 - 14 years, Male

Bulalafurfursa
S.No Activity
PHCU
Mal_Pos.1. 4 5 - 14 years, Female
Mal_Pos.1. 5 >= 15 years, Male
Mal_Pos.1. 6 >= 15 years, Female
Mal_DX. Total number of slides or RDT performed for malaria diagnosis
CA_VIA.1 Number of women aged 30 - 49 screened with VIA for cervical cancer
CA_VIA.1. 1 Normal cervix
CA_VIA.1. 2 Precancerous lesion
CA_VIA.1. 3 Cancerous lesion
CA_SCCAL_RX.1 Number of women aged 30-49 year with cervical lesion received treatment
CA_SCCAL_RX.1. 1 Crayotherapy
CA_SCCAL_RX.1. 2 LEEP
NCDC_DM Diabetes mellitus
NCDC_DM_Sc1 Total number of individuals screened for diabetes in the reporting period
NCDC_DM_Sc1. 1 40 - 49 years, Male
NCDC_DM_Sc1. 2 40 - 49 years, Female
NCDC_DM_Sc1. 7 >=70 years, Male
NCDC_DM_Sc1. 8 >=70 years, Female
Total number of individuals with raised blood sugar among screened for diabetes
NCDC_DM2
in the reporting period
NCDC_DM2. 1 40 - 49 years, Male
NCDC_DM2. 2 40 - 49 years, Female
NCDC_DM2. 7 >=70 years, Male
NCDC_DM2. 8 >=70 years, Female
NCDC_DM_NW3 Total number of new diabetic patients enrolled to care
NCDC_DM_NW3. 1 < 40 years, Male
NCDC_DM_NW3. 2 < 40 years, Female
NCDC_DM_NW3. 3 40 - 49 years, Male
NCDC_DM_NW3. 4 40 - 49 years, Female

Bulalafurfursa
S.No Activity
PHCU
NCDC_DM_NW3. 9 >=70 years, Male
NCDC_DM_NW3. 10 >=70 years, Female
NCDC_DM_N_Rx3. Total number of diabetic patients put on drug treatment in the reporting period
NCDC_DM_TP4 Total number of diabetic patients disaggregated by type
NCDC_DM_TP4. 1 Diabetes mellitus Type I
NCDC_DM_TP4. 2 Diabetes mellitus Type II
NCDC_DM_TP4. 3 Gestational Diabetes mellitus (GDM)
Total number of cohort diabetic patients enrolled to care six month prior to the reporting
NCDC_DM_Rx5.
month
Total number of diabetic patients enrolled to care six month prior to the reporting
NCDC_DM_Rx6
month
NCDC_DM_Rx6. 1 Controlled
NCDC_DM_Rx6. 2 Not controlled
NCDC_DM_Rx6. 3 Lost to follow-up
NCDC_DM_Rx6. 4 Died
NCDC_DM_Rx6. 5 Transferred out
NCDC_HT Hypertension
NCDC_HT_Sc1 Total number of individuals screened for hypertension in the reporting period
NCDC_HT_Sc1. 3 30 - 49 years, Male
NCDC_HT_Sc1. 4 30 - 49 years, Female
NCDC_HT_Sc1. 5 50 - 59 years, Male
NCDC_HT_Sc1. 6 50 - 59 years, Female
NCDC_HT_Sc1. 7 >=70 years, Male
NCDC_HT_Sc1. 8 >=70 years, Female
Total number of individuals with raised blood pressure among screened for
NCDC_HT2
hypertension in the reporting period
NCDC_HT2. 3 30 - 49 years, Male
NCDC_HT2. 4 30 - 49 years, Female
NCDC_HT2. 5 50 - 59 years, Male
NCDC_HT2. 6 50 - 59 years, Female
NCDC_HT2. 7 >=70 years, Male
NCDC_HT2. 8 >=70 years, Female
NCDC_HT_Nw3 Total number of new hypertensive patients enrolled to care
NCDC_HT_Nw3. 1 < 30 years, Male
NCDC_HT_Nw3. 2 < 30 years, Female

Bulalafurfursa
S.No Activity
PHCU
NCDC_HT_Nw3. 3 30 - 49 years, Male
NCDC_HT_Nw3. 4 30 - 49 years, Female
NCDC_HT_Nw3. 5 50 - 59 years, Male
NCDC_HT_Nw3. 6 50 - 59 years, Female
NCDC_HT_Nw3. 7 >=70 years, Male
NCDC_HT_Nw3. 8 >=70 years, Female
NCDC_HT_Nw_Rx3. Total number of hypertensive patients put on drug treatment in the reporting period
NCDC_HT_Nw4 Total number of hypertensive patients enrolled to care disaggregated by stage
NCDC_HT_Nw4. 1 Stage I
NCDC_HT_Nw4. 2 Stage II
NCDC_HT_Nw4. 3 Severe HTN ( Including HTN emergency and urgency)
NCDC_HT_Nw4. 4 Others
Total number of cohort hypertensive patients enrolled to care six month prior to the
NCDC_HT_Rx5.
reporting month
Total number of hypertensive patients enrolled to care six month prior to the
NCDC_HT_Rx6
reporting month
NCDC_HT_Rx6. 1 Controlled
NCDC_HT_Rx6. 2 Not controlled
NCDC_HT_Rx6. 3 Lost to follow-up
NCDC_HT_Rx6. 4 Died
NCDC_HT_Rx6. 5 Transferred out
NCDC_CVD Cardio Vascular Diseases
NCDC_CVD1 Total number of patients assessed for CVD risk
NCDC_CVD1. 1 CVD risk < 10%( Low)
NCDC_CVD1. 2 CVD risk 10%-20%(Moderate)
NCDC_CVD1. 3 CVD risk 20%-30%(High)
NCDC_CVD1. 4 CVD risk >=30%(Very High)
CVD_RX.1. Number of patients with CVD risk >= 30% received treatment during the reporting period
HSQI Quality of health services
OPD_OPAPC.1 Number of outpatient visits
OPD_OPAPC.1. 1 < 5 years, Male
OPD_OPAPC.1. 2 < 5 years, Female
OPD_OPAPC.1. 3 5 - 10 years, Male
OPD_OPAPC.1. 4 5 - 10 years, Female

Bulalafurfursa
S.No Activity
PHCU
OPD_OPAPC.1. 13 >= 66 years, Male
OPD_OPAPC.1. 14 >= 66 years, Female
FRM_HI_OPAPC.1. Number of CBHI members visit made to HF in a month
HSQI_IPD_AR Admission rate
IPD_AR.1. Number of inpatient admissions
Bed occupancy rate
IPD_BOR.1. Length of stay (in days) in the reporting period
IPD_BOR.2. Total number of beds
HSQI_IPD_ALOS Average length of stay
IPD_ALS.1. Number of inpatient discharges
IPD_LoS.1. Total length of stay (in days) during discharge
HSQI_IPD_IMR Inpatient mortality rate
IPD_IMR.1. Number of inpatient deaths in the reporting period
HSQI_BDB_UBDU Proportion of blood units utilized from blood bank service
BDB_UBDR.1. Total units of blood received from NBTS & regional blood banks
TtBD_UBDT.1 Total number of units of blood transfused
TtBD_UBDT.1. 1 direct family replacement
TtBD_UBDT.1. 2 from blood bank
TtBD_UBDT_SATIR Serious Adverse Transfusion Incidents and Reactions
UBDT_SATIR.1. Number of serious adverse transfusion incidents and reactions occurred
HSQI_ERU_MR Emergency unit/department mortality rate
ERU_MR.1 Total death in the emergency unit
ERU_MR.1. 1 < 15 years, Male
ERU_MR.1. 2 < 15 years, Female
ERU_MR.1. 3 >= 15 years, Male
ERU_MR.1. 4 >= 15 years, Female
ERU_ERA.1. Total number of emergency unit attendances
RF_RFR.1 Number of people referred to other health facility
RF_RFR.1. 1 Emergency referral
RF_RFR.1. 2 Non-emergency referral
RTA_RTI.1 Number of road traffic injury cases dis aggregated by accident type
RTA_RTI.1. 1 Vehicle occupant
RTA_RTI.1. 2 Motor cyclist

Bulalafurfursa
S.No Activity
PHCU
RTA_RTI.1. 3 Pedestrian
RTA_RTI.1. 4 Others
HCSM_EDA_TDR Tracer drug availability
EDA_TDR.1. Availability of Amoxicillin
EDA_TDR.2. Availability of Oral Rehydration Salt
EDA_TDR.3. Availability of Zinc
EDA_TDR.4. Availability of Gentamycine
EDA_TDR.5. Availability of Cotrimoxazole 240 mg/ 5ml
EDA_TDR.6. Availability of Magnesium Sulphate Injection
EDA_TDR.7. Availability of Oxytocin Injection
EDA_TDR.8. Availability of Enalapril 10mg tablets
EDA_TDR.9. Availability of Medroxyprogesterone (depo) Injection
EDA_TDR.10. Availability of Glibenclamide 5mg
EDA_TDR.11. Availability of Adrenaline (Epinephrine) injection
EDA_TDR.12. Availability of Pentavalent DPT-Hep-Hib Vaccine
EDA_TDR.13. Availability of Glucose 40%
EDA_TDR.14. Availability of Dextrose in normal saline
EDA_TDR.15. Availability of Ferrous Sailt plus Folic Acid
EDA_TDR.16. Availability of Ciprofloxacin 500 mg tablet
EDA_TDR.17. Availability of Ceftriaxone 1 gm injection
EDA_TDR.18. Availability of Hydralazine injection
EDA_TDR.19. Availability of TDF/3TC/EFV adult
EDA_TDR.20. Availability of TB (RHZE/RH) patient kit
EDA_TDR.21. Availability of Tetanus antitoxine (TAT)
EDA_TDR.22. Availability of Tetracycline Eye Ointment
EDA_TDR.23. Availability of Arthemisin / Lumphantrine
EDA_TDR.24. Availability of Implanon NXT
EDA_TDR.25. Availability of Artesuante injection
HCSM_Dis_PrDF Percentage of Clients with 100% prescribed drugs filled
Dis_PrDF.1. Number of clients who received 100% of prescribed drugs
Dis_DPrR.1. Total number of clients who received prescriptions
EBDM Evidence based decision making
Proportion of facilities which have done LQAS
DQ_DA1. Did the HF conduct LQAS for service report?
DQ_DA.1.1. LQAS first score for service report
DQ_DA.1.2. LQAS last score for service report
DQ_DA2. Did the HF conduct LQAS for OPD report?

Bulalafurfursa
S.No Activity
PHCU
DQ_DA.2.1. LQAS first score for OPD report
DQ_DA.2.2. LQAS last score for OPD report
DQ_DA3. Did the HF conduct LQAS for IPD report?
DQ_DA.3.1. LQAS first score for IPD report
DQ_DA.3.1. LQAS last score for IPD report

Health Center Monthly Service Delivery Report (Yekatit 2013 Megabit 2013 Tir 2013)

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Health Center Monthly Service Delivery Report (Yekatit 2013 Megabit 2013 Tir 2013)

Uploaded by

Copyright:

Available Formats

4/1/2021 Dataset Report

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

Health Center Monthly Service Delivery Report (Yekatit 2013;

You might also like